Cargando…
Bacteriophage therapy to combat bacterial infections in poultry
Infections in poultry are an economic and health problem in Europe and worldwide. The most common infections are associated with salmonellosis, colibacillosis, campylobacteriosis, and others. The prevalence of Campylobacter-positive poultry flocks in European countries varies from 18% to 90%. In the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602926/ https://www.ncbi.nlm.nih.gov/pubmed/28915819 http://dx.doi.org/10.1186/s12985-017-0849-7 |
_version_ | 1783264646710427648 |
---|---|
author | Wernicki, Andrzej Nowaczek, Anna Urban-Chmiel, Renata |
author_facet | Wernicki, Andrzej Nowaczek, Anna Urban-Chmiel, Renata |
author_sort | Wernicki, Andrzej |
collection | PubMed |
description | Infections in poultry are an economic and health problem in Europe and worldwide. The most common infections are associated with salmonellosis, colibacillosis, campylobacteriosis, and others. The prevalence of Campylobacter-positive poultry flocks in European countries varies from 18% to 90%. In the United States, the prevalence of infected flocks is nearly 90%. A similar percentage of infection has been noted for salmonellosis (about 75–90%) and E. coli (90–95%). The occurence of Clostridium perfringens is a major problem for the poultry industry, with some estimates suggesting colonization of as many as 95% of chickens, resulting in clinical or subclinical infections. In the US, annual economic losses due to Salmonella infections run from $1.188 billion to over $11.588 billion, based on an estimated 1.92 million cases. Similar costs are observed in the case of other types of infections. In 2005 economic losses in the the poultry industry due to mortalities reached 1,000,000 USD. Infections caused by these pathogens, often through poultry products, are also a serious public health issue. The progressive increase in the number of multi-drug resistant bacteria and the complete ban on the use of antibiotics in livestock feed in the EU, as well as the partial ban in the US, have led to the growth of research on the use of bacteriophages to combat bacterial infections in humans and animals. The high success rate and safety of phage therapy in comparison with antibiotics are partly due to their specificity for selected bacteria and the ability to infect only one species, serotype or strain. This mechanism does not cause the destruction of commensal bacterial flora. Phages are currently being used with success in humans and animals in targeted therapies for slow-healing infections. They have also found application in the US in eliminating pathogens from the surface of foods of animal and plant origin. At a time of growing antibiotic resistance in bacteria and the resulting restrictions on the use of antibiotics, bacteriophages can provide an alternative means of eliminating pathogens. |
format | Online Article Text |
id | pubmed-5602926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56029262017-09-20 Bacteriophage therapy to combat bacterial infections in poultry Wernicki, Andrzej Nowaczek, Anna Urban-Chmiel, Renata Virol J Review Infections in poultry are an economic and health problem in Europe and worldwide. The most common infections are associated with salmonellosis, colibacillosis, campylobacteriosis, and others. The prevalence of Campylobacter-positive poultry flocks in European countries varies from 18% to 90%. In the United States, the prevalence of infected flocks is nearly 90%. A similar percentage of infection has been noted for salmonellosis (about 75–90%) and E. coli (90–95%). The occurence of Clostridium perfringens is a major problem for the poultry industry, with some estimates suggesting colonization of as many as 95% of chickens, resulting in clinical or subclinical infections. In the US, annual economic losses due to Salmonella infections run from $1.188 billion to over $11.588 billion, based on an estimated 1.92 million cases. Similar costs are observed in the case of other types of infections. In 2005 economic losses in the the poultry industry due to mortalities reached 1,000,000 USD. Infections caused by these pathogens, often through poultry products, are also a serious public health issue. The progressive increase in the number of multi-drug resistant bacteria and the complete ban on the use of antibiotics in livestock feed in the EU, as well as the partial ban in the US, have led to the growth of research on the use of bacteriophages to combat bacterial infections in humans and animals. The high success rate and safety of phage therapy in comparison with antibiotics are partly due to their specificity for selected bacteria and the ability to infect only one species, serotype or strain. This mechanism does not cause the destruction of commensal bacterial flora. Phages are currently being used with success in humans and animals in targeted therapies for slow-healing infections. They have also found application in the US in eliminating pathogens from the surface of foods of animal and plant origin. At a time of growing antibiotic resistance in bacteria and the resulting restrictions on the use of antibiotics, bacteriophages can provide an alternative means of eliminating pathogens. BioMed Central 2017-09-16 /pmc/articles/PMC5602926/ /pubmed/28915819 http://dx.doi.org/10.1186/s12985-017-0849-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Wernicki, Andrzej Nowaczek, Anna Urban-Chmiel, Renata Bacteriophage therapy to combat bacterial infections in poultry |
title | Bacteriophage therapy to combat bacterial infections in poultry |
title_full | Bacteriophage therapy to combat bacterial infections in poultry |
title_fullStr | Bacteriophage therapy to combat bacterial infections in poultry |
title_full_unstemmed | Bacteriophage therapy to combat bacterial infections in poultry |
title_short | Bacteriophage therapy to combat bacterial infections in poultry |
title_sort | bacteriophage therapy to combat bacterial infections in poultry |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602926/ https://www.ncbi.nlm.nih.gov/pubmed/28915819 http://dx.doi.org/10.1186/s12985-017-0849-7 |
work_keys_str_mv | AT wernickiandrzej bacteriophagetherapytocombatbacterialinfectionsinpoultry AT nowaczekanna bacteriophagetherapytocombatbacterialinfectionsinpoultry AT urbanchmielrenata bacteriophagetherapytocombatbacterialinfectionsinpoultry |